Disparities in Treatment of Patients With High-risk Prostate Cancer: Results From a Population-based Cohort
Elyn H. Wang(Yale University), Simon P. Kim(Northwestern University), Neal J. Meropol(Flatiron Health (United States)), Christopher Gonzalez(University Hospitals Cleveland Medical Center), Stephen B. Williams(Cedars-Sinai Medical Center), James B. Yu(Harvard University), Marc C. Smaldone(Fox Chase Cancer Center), Alexander Kutikov(Fox Chase Cancer Center), Hui Zhu(Louis Stokes Cleveland VA Medical Center), Robert Abouassally(University Hospitals Cleveland Medical Center), Nilay D. Shah(Mayo Clinic), Gregory S. Cooper(University Hospitals Case Medical Center)
Cited by 33
Related Papers
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
|Journal of Clinical Oncology|2015|903
Acute Hyperglycemia Attenuates Endothelium-Dependent Vasodilation in Humans In Vivo
|Circulation|1998|804
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
|Journal of Clinical Oncology|2016|654